Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Jul 21, 2017 11:29am

151 Views

Post# 26494997

RE:RE:RE:Same pattern as yesterday

juniper88 wrote: If they do a financing next week, i.e., after the manufacturing inspecition is done then investors will question if something went wrong and the share price will plunge.

The only way I will "swalow the pill" is if an offering is linked to an acquisition that will increase the EPS immediately. I am not at all insterested in putting more money in the coffers just to be safe.

Alternatively, they could do the offering in conjunction with a Nasdaq listing.

Investors would presume the inspection went well and the share price would move up.

I still think this is all noise from the warrants.

bfw

Bullboard Posts

Sirios Resource discovers visible gold in Quebec